BC031441 Inhibitors
Chemical inhibitors of BC031441 employ various mechanisms to impede its function. Staurosporine, a broad-spectrum protein kinase inhibitor, targets the ATP-binding sites of kinases, thereby preventing the phosphorylation events necessary for the activation of BC031441. Similarly, LY294002, which is a specific inhibitor of PI3K, disrupts the PI3K/Akt pathway, a signaling cascade that is often crucial for the activity of proteins like BC031441. By obstructing this pathway, LY294002 ensures that the downstream signaling necessary for BC031441's function is curtailed. Another inhibitor, Rapamycin, acts on mTOR, a kinase involved in cell growth and proliferation, to suppress the activation of targets that BC031441 may require for its function.
Further inhibitory actions include PD98059, which targets MEK1/2 and thereby inhibits the ERK/MAPK pathway, a signaling mechanism that can regulate the activity of BC031441. SB203580 takes a different approach by selectively inhibiting p38 MAP kinase, which may affect BC031441 if its activity or stability is contingent on this stress response pathway. Src family kinases, which can be involved in the activation of BC031441, are targeted by PP2, resulting in the inhibition of BC031441's functional activity. Dasatinib extends this approach by not only inhibiting Src family kinases but also Bcr-Abl, potentially blocking multiple pathways that BC031441 may utilize. Similarly, Sorafenib, a multi-kinase inhibitor, impedes RAF kinases, VEGFR, and PDGFR, which could be involved in the activation of BC031441. SP600125 and ZM447439 target the JNK and Aurora kinases, respectively, both of which could be integral to BC031441's function, particularly regarding stress response and cell cycle progression. Lastly, Lestaurtinib inhibits JAK2, affecting the JAK-STAT signaling pathway, and PD173074 inhibits FGFR, both potentially leading to inhibition of BC031441 by blocking critical signaling pathways it may depend on.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
As a potent inhibitor of protein kinases, Staurosporine can inhibit BC031441 by obstructing the kinase activity required for its function. Specifically, it can prevent the phosphorylation of BC031441 by targeting the ATP-binding sites of kinases that would activate BC031441. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit BC031441 by disrupting the PI3K/Akt signaling pathway. This pathway can be crucial for the activation and function of BC031441, and inhibition by LY294002 prevents its downstream signaling, leading to functional inhibition of BC031441. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and proliferation. By inhibiting mTOR, Rapamycin can suppress the activation of downstream targets necessary for BC031441 function, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that can inhibit BC031441 by preventing the activation of the ERK/MAPK pathway. Since this pathway is often involved in the regulation of proteins like BC031441, blocking it with PD98059 can inhibit the functional activity of BC031441. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase which is involved in stress responses. The inhibition of p38 MAP kinase can lead to the functional inhibition of BC031441 if it relies on this pathway for its activation or stability. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor that can inhibit BC031441 by preventing Src-mediated activation or phosphorylation, which might be necessary for BC031441's functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Bcr-Abl and Src family kinases, which may interact with BC031441. By blocking these kinases, Dasatinib can inhibit downstream signaling pathways that are essential for the functional activity of BC031441. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting RAF kinases, VEGFR, and PDGFR. The inhibition of these kinases can prevent the activation of signaling pathways necessary for BC031441's function, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the MAPK signaling pathways. By inhibiting JNK, SP600125 can inhibit BC031441 by preventing the activation of downstream targets that could be necessary for the function of BC031441. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM447439 targets Aurora kinases, which are critical for cell cycle progression. Inhibition of Aurora kinases may block the cell cycle-related functions of BC031441, leading to its functional inhibition. | ||||||